Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Core Insights - Kiniksa Pharmaceuticals plans to initiate a Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026 [1][2][4] - KPL-387 is a monoclonal antibody targeting IL-1R1, which may allow for monthly subcutaneous dosing, enhancing treatment options for patients [2][4][8] - The company will discontinue the development of abiprubart for Sjögren's Disease and is exploring strategic alternatives for this asset [1][4][13] Company Strategy - Kiniksa focuses on developing therapies for diseases with unmet needs, particularly in cardiovascular indications [1][4] - The company has successfully commercialized ARCALYST, generating over $800 million in product revenue since its launch in 2021, and has become cash flow positive annually [2][4] - Kiniksa aims to increase its market penetration in recurrent pericarditis with ARCALYST while advancing KPL-387 [2][4] Product Development - KPL-387 is currently undergoing a Phase 1 clinical trial, with topline data supporting the potential for monthly subcutaneous dosing [4][8] - Kiniksa is also advancing KPL-1161, another monoclonal antibody with a target profile of quarterly subcutaneous dosing [4][9] - The company has engaged with the FDA regarding the development of KPL-387 and plans to initiate further clinical trials [2][4][13]